Autonomix Medical Inc (AMIX) Noticias

Form 8-K - Current report

Autonomix Medical, Inc. Announces Closing of $10.0 Million Underwritten Public Offering Including Partial Exercise of Over-Allotment Option

THE WOODLANDS, TX, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or...

Form 424B4 - Prospectus [Rule 424(b)(4)]

Form EFFECT - Notice of Effectiveness

Autonomix Medical, Inc. Announces Pricing of $9.0 Million Underwritten Public Offering

THE WOODLANDS, TX, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or...

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Autonomix Medical, Inc. Reports Second Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update

Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer; Preliminary results...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form S-1 - General form for registration of securities under the Securities Act of 1933

Autonomix Medical, Inc. Reports New Positive Topline Results from First 15 Patients’ 7-Day Data Highlighting Significant Impact on Treatment of Pancreatic Cancer Pain with Maintained Pain Reduction

79% responder rate achieved with zero opioid use and quality of life improvement at 7 days post-procedure...

Autonomix Medical, Inc.’s Dr. Robert Schwartz Discusses What Positive 4-6 Week Follow-Up Data Means from Lead-In Patients in Ongoing Human Clinical Trial

Access the Virtual Investor “What This Means” Segment here THE WOODLANDS, TX, Oct. 30, 2024 (GLOBE NEWSWIRE...

Positive Preliminary Results Demonstrate Autonomix’s Proprietary RF Ablation Technology’s Ability to Reduce Opioid Use in Ongoing Human Clinical Trial

100% of the responder group went to zero opioid use at 4-6 weeks post-procedure Up to 75% of late-stage...

Form 8-K - Current report

Autonomix Medical, Inc. to Participate in a Virtual Investor “What This Means” Segment on Wednesday, October 30th

THE WOODLANDS, TX, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or...